This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)

This study has been completed.
Sponsor:
Collaborator:
The University of Texas at San Antonio
Information provided by (Responsible Party):
University of Florida
ClinicalTrials.gov Identifier:
NCT00994682
First received: October 12, 2009
Last updated: February 20, 2017
Last verified: February 2017
October 12, 2009
February 20, 2017
December 2008
December 2014   (Final data collection date for primary outcome measure)
Liver Histology (Using Kleiner et al Criteria, Hepatology 2005) [ Time Frame: At 18 months ]

Number of patients with reduction of at least 2 points in the nonalcoholic fatty liver disease activity score (NAS) (with reduction in at least 2 different histological categories) without worsening of fibrosis. NAS is the sum of the separate scores for steatosis (0-3), hepatocellular ballooning (0-2) and lobular inflammation (0-3), and ranges from 0-8 .

The scoring system is based on the following grading:

Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis.

Liver Histology (Using Kleiner et al Criteria, Hepatology 2005) [ Time Frame: At 18 (2nd biopsy) and 36 (3rd biopsy) months. ]
Complete list of historical versions of study NCT00994682 on ClinicalTrials.gov Archive Site
  • Number of Participants With Resolution of NASH [ Time Frame: Month 18 ]
    Resolution of NASH was defined as absence of NASH after 18 months of therapy in patients with definite NASH (presence of zone 3 accentuation of macrovesicular steatosis of any grade, hepatocellular ballooning of any degree, and lobular inflammatory infiltrates of any amount) at baseline.
  • Mean Individual Histological Scores [ Time Frame: Baseline and Month 18 ]
    Mean change in individual scores compared to baseline. Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis
  • Individual Histological Scores [ Time Frame: Month 18 ]

    Number of patients with improvement of at least 1 grade in each of the histological parameters.

    Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal, 1A = Mild, zone 3, perisinusoidal "delicate" fibrosis; 1B = Moderate, zone 3, perisinusoidal "dense" fibrosis; 1C = Portal/periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis

  • Mean Individual Histological Scores [ Time Frame: Month 36 ]
    Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis
  • Liver Transaminases (AST and ALT). [ Time Frame: 18 and 36 months ]
  • Liver Fat by Magnetic Resonance and Spectroscopy (MRS). [ Time Frame: 18 months ]
    Liver fat content was calculated as the fat fraction: 100*(area under the curve [AUC] of fat peak / [AUC of fat peak + AUC of water peak]).
  • Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) [ Time Frame: 18 and 36 months ]
    Homeostatic model assessment of insulin resistance (HOMA-IR) is a method for assessing insulin resistance (IR) from basal fasting plasma glucose (FPG) and fasting plasma insulin (FPI). It is calculated as (FPG x FPI)/405.
  • Hepatic Insulin Sensitivity [ Time Frame: 18 months ]
    Suppression of endogenous glucose production (Supp EGP) by low dose insulin (i.e., percentage of reduction of EGP with low dose insulin infusion compared to the baseline state). This was calculated as: 100*((EGP without insulin - EGP with insulin infusion)/EGP without insulin). All measurements are obtained at the same time point during an euglycemic insulin clamp.
  • Adipose Tissue Insulin Sensitivity [ Time Frame: 18 months ]
    Suppression of free fatty acids by low dose insulin (i.e., percentage of reduction of plasma FFA with low dose insulin infusion compared to the baseline state). This was calculated as: 100*((plasma FFA without insulin - plasma FFA with insulin infusion)/plasma FFA without insulin). All measurements are obtained at the same time point during an euglycemic insulin clamp.
  • Skeletal Muscle Insulin Sensitivity [ Time Frame: 18 months ]
    Rate of glucose disappearance (Rd) during high-dose insulin infusion. The rate of plasma glucose disappearance was calculated using Steele's non-steady-state equation.
  • Body Mass Index (BMI) [ Time Frame: Months 18 and 36 ]
  • Total Body Fat [ Time Frame: Months 18 ]
    Total body fat measured by dual-energy x-ray absorptiometry (DXA)
  • Plasma Biomarkers Relevant to Hepatic Inflammation, Apoptosis and Fibrosis (Adiponectin). [ Time Frame: 18 and 36 months ]
  • Plasma Biomarkers Relevant to Hepatic Inflammation, Apoptosis and Fibrosis (CK-18). [ Time Frame: 18 and 36 months ]
  • Prevention of the Onset of T2DM and/or Reversal From IFG/IGT to NGT in Non-diabetics. [ Time Frame: 18 months ]
    Number of patients developing T2DM and number of patients regressing to NGT among patients with prediabetes (IFG/IGT).
  • Osteoporotic Fractures [ Time Frame: 18 and 36 months ]
    Number of patients with osteoporotic fractures
  • Molecular Pathways of Liver Glucose and Lipid Signaling; Inflammatory Pathways; Oxidative Stress; Other. [ Time Frame: At 18 (2nd liver biopsy) and 36 (3rd liver biopsy) months. ]
  • Bone Mineral Density [ Time Frame: 18 and 36 months ]
    Bone mineral density measured at the levels of spine, femoral neck, hip, and wrist by DXA.
  • Liver Fat by Magnetic Resonance and Spectroscopy (MRS). [ Time Frame: At 18 (2nd MRS) and 36 (3rd MRS) months. ]
  • Liver transaminases. [ Time Frame: For up to 36 months (at 1-2 month intervals during the study). ]
  • Plasma biomarkers relevant to hepatic inflammation, apoptosis and fibrosis. [ Time Frame: Up to 36 months ]
  • Assessment of hepatic, muscle and adipose tissue insulin sensitivity. [ Time Frame: At 18 (2nd insulin clamp) and 36 (3rd insulin clamp) months. ]
  • Evaluation of insulin secretion and glucose tolerance during an oral glucose tolerance test (OGTT). [ Time Frame: At 18 (2nd OGTT) and 36 (3rd OGTT) months. ]
  • Prevention of the onset of T2DM and/or reversal from IGT to NGT in non-diabetics. [ Time Frame: At 18 (2nd OGTT) and 36 (3rd OGTT) months. ]
  • Anthropometric measurements (body weight, W/H ratio, total body fat by DXA, visceral fat by MRI). [ Time Frame: At 18 (2nd DXA, MRI) and 36 months (3rd DXA, MRI). ]
  • Fractures, bone density (DXA) and plasma measurements of bone metabolism. [ Time Frame: At 18 (2nd DXA, bone metabolism measurements) and 36 (3rd DXA, bone metabolism measurements) months ]
  • Molecular Pathways of Liver Glucose and Lipid Signaling; Inflammatory Pathways; Oxidative Stress; Other. [ Time Frame: At 18 (2nd liver biopsy) and 36 (3rd liver biopsy) months. ]
Not Provided
Not Provided
 
University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)
Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM).
Obesity and Type 2 diabetes are creating a silent epidemic, Non-alcoholic fatty liver disease, which is a chronic liver disease associated with insulin resistance, impaired glucose intolerance, and hepatic fat accumulation. The thiazolidinedione pioglitazone improves glucose/lipid metabolism and histology in NASH by improving insulin resistance in the liver/peripheral/adipose tissues and reducing subclinical inflammation. The aim of this study is to assess the underlying mechanisms at the clinical and molecular level and the long-term efficacy and safety of pioglitazone in NASH in a multiethnic cohort of subjects (predominantly Hispanics, Caucasians and African-Americans - the most common ethnic groups locally) and examine the response including patients with normal glucose tolerance, impaired glucose tolerance or established type 2 diabetes mellitus (T2DM).

NASH is a disease characterized by elevated plasma aminotransferases and histopathological changes in liver characterized by hepatocellular steatosis, chronic inflammation and perisinusoidal fibrosis. NASH affects (~30-40%) of obese and type 2 diabetic subjects. While the pathogenesis of NASH is poorly understood, there is consensus that insulin resistance and its associated abnormalities in lipid metabolism play a key role in the development of liver fat accumulation. Insulin resistance in nonalcoholic steatohepatitis is frequently associated with chronic hyperinsulinemia, hyperglycemia, and an excessive supply of plasma free fatty acids to the liver. This in turn promotes hepatic lipogenesis. Pioglitazone, a thiazolidinedione (TZD), reverses these abnormalities by ameliorating insulin resistance in adipose tissue, liver and muscle. TZDs decrease excessive ectopic triglyceride accumulation in liver and muscle, reduce visceral fat, and redistribute fat to subcutaneous adipose stores. We have shown in a proof-of-concept 6-month study that pioglitazone is safe and effective for the treatment of T2DM. Patients with nonalcoholic steatohepatitis are also characterized by a low plasma adiponectin level. Thiazolidinediones increase plasma adiponectin levels, may activate AMP-activated protein kinase, stimulate hepatic/muscle fatty acid oxidation, and inhibit hepatic fatty acid synthesis in NASH nonalcoholic steatohepatitis. Thiazolidinediones also have antiinflammatory effects which are believed to be of value for therapy for NASH.

In order to evaluate this hypothesis, the investigators will treat for up to 36 months a group of patients with impaired (IGT) glucose tolerance and T2DM patients recruited from the University Hospital and medical school clinics and by newspaper add targeting the San Antonio and South Texas geographical area, with pioglitazone in a randomized, double-blinded, placebo-controlled trial. The primary endpoint will be liver histologic response assessed by liver biopsy performed at 18 and at 36 months of treatment.

Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
  • Nonalcoholic Steatohepatitis
  • Nonalcoholic Fatty Liver Disease
  • Type 2 Diabetes Mellitus
  • Drug: Pioglitazone study drug
    30 mg per day orally for 8 weeks, and if well tolerated, titrated to 45 mg per day until the end of 18 months
    Other Name: Actos (brand name), manufactured by Takeda Pharmaceuticals.
  • Drug: Placebo
    An oral tablet identical to pioglitazone will be given once daily but without active drug for 18 months.
  • Drug: Pioglitazone Open Label
    Patients in both arms were placed open label pioglitazone for an additional 18 months after successfully completing the double-blind, placebo-controlled portion of the study design.
    Other Name: Actos (brand name), manufactured by Takeda Pharmaceuticals.
  • Active Comparator: Pioglitazone
    After all patients receive dietary counseling at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
    Interventions:
    • Drug: Pioglitazone study drug
    • Drug: Pioglitazone Open Label
  • Placebo Comparator: Placebo
    After dietary counseling to all patients at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
    Interventions:
    • Drug: Placebo
    • Drug: Pioglitazone Open Label
Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, Tio F, Hardies J, Darland C, Musi N, Webb A, Portillo-Sanchez P. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016 Sep 6;165(5):305-15. doi: 10.7326/M15-1774. Epub 2016 Jun 21.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
176
December 2014
December 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Be able to communicate meaningfully with the investigators and be legally competent to provide written informed consent.
  2. Age range between 18 to 70 years (inclusive).
  3. Female patients must be non-lactating and must either be at least one year post-menopausal, or be using adequate mechanical contraceptive precautions (i.e. intrauterine device, diaphragm with spermicide, condom with spermicide), or be surgically sterilized (i.e. bilateral tubal ligation, bilateral oophorectomy). Female patients who have undergone a hysterectomy are eligible for participation in the study. Female patients (except for those patients who have undergone a hysterectomy or a bilateral oophorectomy) are eligible only if they have a negative pregnancy test throughout the study period. Patients on oral contraceptives or an hormonal implant will be excluded (patches are acceptable as they deliver much lower estrogen systemically).
  4. Participants must have the following laboratory values:

    • Hemoglobin ≥ 12 gm/dl in males, or ≥ 11 gm/dl in females,
    • WBC count ≥ 3,000/mm3
    • Neutrophil count ≥ 1,500/mm3
    • Platelets ≥ 100,000/mm3
    • Albumin ≥3.0 g/dl
    • Serum creatinine ≤ 1.8 mg/dl
    • Creatinine phosphokinase ≤ 2 times upper limit of normal
    • AST and ALT ≤ 3.0 times upper limit of normal
    • Alkaline phosphatase ≤ 2.5 times upper limit of normal
  5. A diagnosis of NASH by liver biopsy performed within the past 6 months,

Exclusion Criteria:

  1. Any cause of chronic liver disease other than NASH (such as -but not restricted to- alcohol or drug abuse, medication, chronic hepatitis B or C, autoimmune, hemochromatosis, Wilson's disease, alpha1-antitrypsin deficiency).
  2. Any clinical evidence or history of ascitis, bleeding varices, or spontaneous encephalopathy.
  3. Current history of alcohol abuse (alcohol consumption greater than 20 grams of ethanol per day).
  4. Prior surgical procedures to include gastroplasty, jejuno-ileal or jejunocolic bypass.
  5. Prior exposure to organic solvents such as carbon tetrachloride.
  6. Total parenteral nutrition (TPN) within the past 6 months.
  7. Subjects with type 1 diabetes mellitus.
  8. Patients on chronic medications with known adverse effects on glucose tolerance levels unless the patient has been on a stable dose of such agents for 4 weeks before entry into the study. Patients on estrogens or other hormonal replacement therapy, tamoxifen, raloxifene, oral glucocorticoids or chloroquine will be excluded.
  9. Patients with a history of clinically significant heart disease (New York Heart Classification greater than grade II), peripheral vascular disease (history of claudication), or diagnosed pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation).
  10. Patients with severe osteoporosis.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00994682
HSC20070654
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Not Provided
University of Florida
University of Florida
The University of Texas at San Antonio
Principal Investigator: Kenneth Cusi, M.D. University of Florida
University of Florida
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP